Pfizer's passive 7.2% stake signals strategic interest in TRex Bio's pipeline, likely via a prior investment round. Monitor for potential partnership or licensing discussions, though the 13G certification precludes activist intent. The proximity to Johnson & Johnson's 13G filing (1 day prior) suggests multiple pharma investors are accumulating positions.
Price Chart
Executive Summary
Pfizer Inc. and its subsidiary Pfizer Ventures (US) LLC disclosed a 7.2% passive stake in TRex Bio, Inc. via a Schedule 13G filed October 16, 2026. The filing confirms Pfizer's ownership of 1,965,066 shares of common stock, with 1,265,066 shares held directly by Pfizer Ventures. This is a new position filed under Rule 13d-1(c), indicating no intent to influence control.
Key Financial Metrics
Key Facts
- Pfizer Inc. and Pfizer Ventures (US) LLC filed a Schedule 13G disclosing beneficial ownership of 1,965,066 shares of TRex Bio common stock.
- The stake represents 7.2% of TRex Bio's 27,445,682 outstanding shares as of October 8, 2026.
- Pfizer Ventures directly holds 1,265,066 shares (4.6% of outstanding).
- The filing is under Rule 13d-1(c), certifying passive investment intent with no purpose of changing or influencing control.
- This is a new filing (not an amendment) and was filed one day after a prior SC 13G by Johnson & Johnson Innovation-JJDC, Inc.
Financial Impact
Pfizer's 7.2% stake is a significant passive position in a clinical-stage biotech, but no transaction price or dollar value is disclosed in the filing.
Risk Factors
- Passive 13G status could convert to 13D if Pfizer later seeks board representation or strategic influence.
- No disclosure of cost basis or investment intent beyond passive — stake could be reduced without public notice.
- Biotech sector risk: TRex Bio's valuation depends on clinical trial outcomes and regulatory approvals.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000078003-26-000118 |
| Document: 0000078003-26-000118-index-headers.html | 0000078003-26-000118 |
| Document: 0000078003-26-000118-index.html | 0000078003-26-000118 |
| Document: 0000078003-26-000118.txt | 0000078003-26-000118 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.79 (−6.82%) |
Oct 16, 2026 11d ago | SC 13D | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.79 (−6.82%) |
Oct 16, 2026 11d ago | SC 13D | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.79 (−1.57%) |
Oct 15, 2026 11d ago | Insider Cluster | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.79 (−1.57%) |
Oct 15, 2026 12d ago | SC 13G | $14.16 $14.01 | ▼ −1.06% | ▲ +0.05% | $13.79 (−2.61%) |
Oct 13, 2026 13d ago | Press Release | $13.50 $14.16 | ▲ +4.89% | ▲ +4.60% | $13.79 (+2.15%) |
Oct 9, 2026 17d ago | 424B4 | $14.03 $13.60 | ▼ −3.06% | ▼ −3.05% | $13.79 (−1.71%) |
Oct 9, 2026 18d ago | EFFECT | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.79 (−1.50%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.79 (−1.50%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.79 (−1.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers